NewsEvents

Your Yourlocation: Home > The use of Respimat inhalation of tiotropium bromide(136310-93-5) is safe and effective in the treatment of COPD

Previous studies of tiotropium bromide(136310-93-5) in the treatment of chronic obstructive pulmonary disease (COPD) have shown that inhalation of 5 μg of tiotropium bromide using a Respimat device is similar to the inhalation of 18 μg of tiotropium bromide using a HandiHaler device. Compared with the placebo group, the mortality rate in the HandiHaler group was lower and the mortality rate in the Respimat group was higher.

Dr. Wise, of the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (TIOSPIR Study Group) conducted a study showing that inhalation of tiotropium bromide(136310-93-5) using Respimat or HandiHaler devices in patients with COPD and the role of reducing the risk of acute exacerbations. The results were recently published in the NEJM magazine.

The study was a large, randomized, double-blind, controlled trial involving 17135 patients with COPD to compare the efficacy and safety of inhalation of 2.5 μg or 5 μg of tiotropium bromide using a Respimat device and inhalation of 18 μg of tiotropium bromide using a HandiHaler device Sex.

The primary end point of the study was the risk of death for the subjects (non-inferiority study: Respimat group inhaled tiotropium 2.5 or 5 μg, day 1 VS HandiHaler group inhaled tiotropium 18 g, once daily). The risk of acute COPD episodes for the first time after enrollment (Epidemiological study: Respirat group inhaled tiotropium 5 μg vs HandiHaler group inhaled tiotropium 18 μg). The study also evaluated the cardiovascular safety of the subjects, including the safety of the two inhalers used in stable heart disease patients.

The results showed that there was no significant difference in the inhalation of 5 μg or 2.5 μg of tiotropium bromide(136310-93-5) using a Respimat device inhalation with 18% tiotropium bromide using a HandiHaler device in terms of drug safety for patients with COPD and a reduced risk of acute exacerbation.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved